youtube_live
Q3 2026 earnings • released • EPS beat +11.45% • Revenue beat +3.01%
See resultschevron_right
AMGN34:BVMF
Amgen Inc. BDR
R$93.06
arrow_downward
-0.77%(-0.72) 1D
Nov 5, 1:05:17 PM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMGN34...
Open
R$94.72
High
R$94.72
Low
R$93.06
Mkt. cap
253.43B
Avg. vol.
418.00
Volume
52.00
52-wk high
R$94.72
52-wk low
R$47.76
Shares outstanding
540.63M
No. of employees
32K
Open
R$94.72
High
R$94.72
Low
R$93.06
Mkt. cap
253.43B
Avg. vol.
418.00
Volume
52.00
52-wk high
R$94.72
52-wk low
R$47.76
Shares outstanding
540.63M
No. of employees
32K
News stories
From web sources and news partners
The Motley Fool
·
43 minutes ago
Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?
GuruFocus
·
18 hours ago
Amgen Inc (AMGN) Shares Surge 3.7% -- What GF Score of 85 Tells Investors
marketscreener.com
·
22 hours ago
Amgen's Diversified Base Business Warrants Higher Multiple, UBS Says
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc. BDR
CEORobert A. Bradway
Employees31.5K
Founded1980
HeadquartersThousand Oaks, California, United States
SectorBiotechnology
Industry-
Websiteamgen.com